WHO Launches Ebola Treatment Trials in DRC — First Patients Due Next Week

June 28, 2026 5 min read

Health officials confirmed Friday that two experimental Ebola treatments will enter human trials in the Democratic Republic of Congo starting next week, a development that could reshape how the deadly virus is managed during active outbreaks. The World Health Organisation announced the accelerated timeline in Geneva, saying the Phase 2 trials would assess whether the two drugs can reduce mortality rates among infected patients. The trials represent a rare opportunity to gather real-world efficacy data during an ongoing outbreak rather than waiting for a future epidemic to strike.

Drug Selection and Protocol Details

The WHO selected the two investigational treatments based on preliminary data from previous outbreaks. According to the organisation, both drugs showed promise in laboratory settings and animal models, though human efficacy data remains limited. Officials declined to name the specific pharmaceutical companies manufacturing the compounds, citing ongoing contractual negotiations. The trials will follow a randomised controlled design, with patients in affected health zones receiving either one of the experimental treatments or standard supportive care.

The protocol requires a minimum of 200 participants across multiple treatment sites. Investigators will monitor patients for 28 days to assess safety and preliminary effectiveness. Independent ethics committees in Congo approved the study design last month, clearing the final regulatory hurdle before enrolment could begin. Health workers treating Ebola patients in North Kivu, Ituri, and South Kivu provinces will be eligible to participate in the programme.

Why Congo Became the Testing Ground

The Democratic Republic of Congo has endured more than a dozen documented Ebola outbreaks since the virus was first identified in 1976. The current outbreak, centred in the eastern provinces, has strained local health infrastructure and killed hundreds of people over the past two years. Conditions in affected communities — including displacement camps, dense urban populations, and cross-border movement — make the region ideal for evaluating how treatments perform outside controlled clinical settings.

Local health authorities have battled not only the virus but also community resistance to medical interventions. Previous vaccination campaigns encountered suspicion in some villages, forcing officials to adopt increasingly community-driven outreach strategies. Researchers hope that offering access to experimental treatments alongside standard care might build trust while simultaneously generating the data needed for broader approval. The approach mirrors a strategy employed during the 2014-2016 West African outbreak, when clinical trials helped identify effective therapeutics.

Logistical Hurdles on the Ground

Organisers face significant logistical challenges in delivering the trials across a geographically dispersed area. Roads in North Kivu remain dangerous in some stretches due to armed group activity, complicating the transport of temperature-sensitive medications. The WHO has pre-positioned supplies at regional hubs and trained additional staff to administer infusions at remote health posts. Cold chain equipment has been installed at 14 sites across affected provinces.

Global Health Implications

Successful trial results could trigger a cascade of policy changes affecting how the WHO stockpiles and deploys Ebola treatments during future outbreaks. Currently, no Ebola therapeutic holds widespread regulatory approval for routine use, leaving clinicians with limited tools beyond supportive care such as fluid replacement and fever management. If either drug demonstrates clear benefit, manufacturers would have stronger incentive to scale up production and seek formal authorisation from agencies including the US Food and Drug Administration and the European Medicines Agency.

The initiative aligns with the WHO's broader strategy to develop a portfolio of outbreak-ready medical countermeasures. The organisation has committed to maintaining a global research roster of potential pandemic threats, prioritising pathogens with high mortality rates and limited treatment options. Ebola sits near the top of that list due to its propensity for explosive nosocomial transmission and its historical fatality rate exceeding 50 percent in some outbreaks.

Community Engagement Strategy

Health officials acknowledged that recruiting patients for a clinical trial during an active outbreak requires delicate community engagement. The WHO has partnered with local leaders, religious figures, and survivor networks to explain the trial's purpose and address misconceptions about experimental medicine. Trained communicators will visit households in affected areas before enrolment begins, answering questions and distributing printed materials in local languages including Swahili and Lingala.

Survivors of previous Ebola infections will play a visible role in the outreach effort. Researchers have documented cases where survivors' testimonials shifted community attitudes toward accepting medical interventions. The trial protocol includes provisions allowing patients to withdraw at any time without affecting their access to standard care, a protection designed to ensure voluntary participation rather than coercion.

Regulatory and Funding Landscape

The trials received funding from a coalition of government donors and private foundations that support epidemic preparedness research. Financial details remain undisclosed, though the WHO indicated the budget covers drug manufacturing, staff training, and data management systems. Regulatory submissions have been filed in the United Kingdom and Canada, where accelerated approval pathways for outbreak-relevant treatments exist. Officials expect reviews to conclude within 18 months of receiving complete trial data.

What Happens Next

Enrolment is scheduled to begin Monday in three pilot health facilities before expanding to additional sites within two weeks. Investigators will conduct an interim analysis once half the planned participants have completed follow-up, potentially allowing early termination if one treatment shows overwhelming benefit or harm. The WHO plans to publish preliminary results in a public repository regardless of outcome, a policy designed to ensure transparency and avoid publication bias.

Researchers and public health officials will be watching closely. If the trials succeed, they could establish a template for rapidly evaluating treatments during future outbreaks rather than waiting years for regulatory approvals. The next critical milestone arrives in approximately six weeks, when the first batch of safety data becomes available for independent review.